Navigation Links
Moderna Therapeutics Named to the World Economic Forum's Community of "Global Growth Companies"
Date:10/24/2013

CAMBRIDGE, Mass., Oct. 24, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA (mRNA) therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, has been named to the World Economic Forum's community of the fastest-growing "Global Growth Companies" (GGC).

Moderna is one of three North American global health companies to receive this year's honor and is recognized by the Forum for being an industry leader in innovative mRNA therapeutics. The company's initial focus is on developing and commercializing its therapeutics in oncology and rare diseases, and it will partner future drug candidates in areas such as cardiovascular and metabolic disorders. In addition, Moderna was recently awarded a grant by the United States Defense Advanced Research Projects Agency (DARPA) to develop mRNA drugs to protect against a wide range of known and unknown emerging infectious diseases and engineered biological threats.

"When choosing entrants to our Community of Global Growth Companies, we assess companies on their business model, annual revenues and growth rates, executive leadership and market position," said David Aikman, Managing Director, Head of New Champions, World Economic Forum. "Moderna is a pioneering group with clear potential to shape the future in its relevant business sectors and so is a perfect fit to our GGC community."

"We take our commitment to delivering on the promise of messenger RNA therapeutics very seriously, as it has the potential to transform the lives of patients with a wide range of diseases, including many that are untreatable today," said Stephane Bancel, president and founding CEO of Moderna. "We are honored to be recognized for our efforts to advance our platform and ensure its potential is realized on a global scale, and we look forward to being a member of the World Economic Forum community."

The World Economic Forum's Community of Global Growth Companies (GGC) was formed in 2007 to engage dynamic high-growth companies with the potential to be tomorrow's industry leaders and to become a driving force of economic and social change. Members of the Community of Global Growth Companies convene every year at the Chinese-hosted Annual Meeting of the New Champions and at the World Economic Forum's regional meetings, and collaborate through the private area of the World Economic Forum's website, an exclusive online networking platform for business and government leaders. Learn more at http://www.weforum.org/ggc.

About the World Economic Forum
The World Economic Forum is an independent international organization committed to improving the state of the world by engaging leaders in partnerships to shape global, regional and industry agendas. Incorporated as a foundation in 1971, and headquartered in Geneva, Switzerland, the World Economic Forum is impartial and not-for-profit; it is tied to no political, partisan or national interests (http://www.weforum.org).

About Moderna Therapeutics
Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate, including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutic areas in order to rapidly deliver this innovation to patients. Moderna is a privately held company based in Cambridge, Massachusetts. Visit www.modernatx.com to learn more.

For information contact:
Maria Favorito
617-761-6720
Maria.Favorito@fkhealth.com

 


'/>"/>
SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013
2. Study Published in Nature Biotechnology Demonstrates Ability of Modernas Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
3. Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development
4. Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer
5. Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
6. United Therapeutics Corporation to Announce Third Quarter 2013 Financial Results Before Market Open on Tuesday, October 29, 2013
7. PTC Therapeutics Expands Management Team
8. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
9. Convoy Therapeutics Granted Patent for Proprietary SPACE Technology
10. Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
11. Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... and business process optimization firm for the life sciences and healthcare industries, announces ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud ...
Breaking Biology Technology:
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
Breaking Biology News(10 mins):